ArticleNature2026
Netrin1 blockade alleviates resistance to chemotherapy in pancreatic cancer.
Abstract readClinical Trial, Phase I
In one paragraph
Article in Nature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Epithelial-mesenchymal transition in carcinoma: navigating phenotypic states to target resistance and metastasis.Cancer metastasis reviews · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors.
Gael RothUniv. Grenoble Alpes, Hepato-Gastroenterology and Digestive Oncology, CHU Grenoble Alpes, Grenoble, France. GRoth@chu-grenoble.fr.
Pascal ArtruHepato-Gastroenterology Department, Hôpital Jean-Mermoz, Lyon, France.
Olivier BoucheCHU Reims, Université Reims Champagne Ardenne, Reims, France.
Nicolas WillietDepartment of Hepatogastroenterology and Gastrointestinal Oncology, University Institute of Cancerology and Hematology of Saint-Etienne (ICHUSE), Targeting Research Unit in Oncology at the University Hospital of Saint-Etienne (URCAS), Saint-Priest-en-Jarez, France.
Julien GhelfiUniv. Grenoble Alpes, Department of Radiology, CHU Grenoble Alpes, Institute for Advanced Biosciences, CNRS UMR 5309-INSERM U1209, Grenoble, France.
Anthony TurpinMedical Oncology Department, Lille University Hospital, University of Lille- UMR9020 CNRS, U1366 INSERM, CHU de Lille, Lille, France.
Astrid LievreDepartment of Gastroenterology, Rennes University Hospital, INSERM UMR1242 Oncogenesis Stress Signaling, Rennes 1 University, Rennes, France.
Jean-Frédéric BlancService d'Hépato-Gastroentérologie et d'Oncologie Digestive, Groupe Hospitalier Haut-Lévêque, CHU Bordeaux, Pessac, France.
Camille EvrardPoitiers University, Department of Medical Oncology, CHU Poitiers, PRODICET UR 24144, Poitiers, France.ORCID http://orcid.org/0000-0003-3147-1350
Jean-Baptiste BachetSorbonne University, Department of Gastroenterology and Digestive Oncology, Pitié-Salpêtrière Hospital, Paris, France.ORCID http://orcid.org/0000-0003-4337-286X
Pauline ParentMedical Oncology Department, Lille University Hospital, University of Lille- UMR9020 CNRS, U1366 INSERM, CHU de Lille, Lille, France.
Marc ManceauUniv. Grenoble Alpes, Inserm, CHU Grenoble Alpes, CIC1406, Grenoble, France.
Matthieu RoustitUniv. Grenoble Alpes, Inserm, CHU Grenoble Alpes, CIC1406, Grenoble, France.ORCID http://orcid.org/0000-0003-4475-1626
Anna BorowikUniv. Grenoble Alpes, Hepato-Gastroenterology and Digestive Oncology, CHU Grenoble Alpes, Grenoble, France.ORCID http://orcid.org/0000-0003-2207-8311
Victoire GrangerUniv. Grenoble Alpes, Hepato-Gastroenterology and Digestive Oncology, CHU Grenoble Alpes, Grenoble, France.
Aurélie DurandUniv. Grenoble Alpes, Hepato-Gastroenterology and Digestive Oncology, CHU Grenoble Alpes, Grenoble, France.
Christelle d'EngremontUniv. Grenoble Alpes, Hepato-Gastroenterology and Digestive Oncology, CHU Grenoble Alpes, Grenoble, France.
Edouard GirardCNRS, UMR 5525, VetAgro Sup, Grenoble INP, Chirurgie digestive, CHU Grenoble Alpes, TIMC, Université Grenoble Alpes, Grenoble, France.
Mircea ChiricaCNRS, UMR 5525, VetAgro Sup, Grenoble INP, Chirurgie digestive, CHU Grenoble Alpes, TIMC, Université Grenoble Alpes, Grenoble, France.
Nicolas BraissandUniversité Lyon 1, Centre Léon Bérard, INSERM U1052-CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon (CRCL), Apoptosis, Cancer and Development Laboratory, Equipe Labellisée 'La Ligue', LabEx DEVweCAN, Institut PLAsCAN, Lyon, France.
Nicolas RamaUniversité Lyon 1, Centre Léon Bérard, INSERM U1052-CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon (CRCL), Apoptosis, Cancer and Development Laboratory, Equipe Labellisée 'La Ligue', LabEx DEVweCAN, Institut PLAsCAN, Lyon, France.ORCID http://orcid.org/0000-0003-1614-7755
Eugénie ModoloUniversité Lyon 1, Centre Léon Bérard, INSERM U1052-CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon (CRCL), Apoptosis, Cancer and Development Laboratory, Equipe Labellisée 'La Ligue', LabEx DEVweCAN, Institut PLAsCAN, Lyon, France.ORCID http://orcid.org/0009-0008-0853-1689
Hector Hernandez-VargasGenomics Consulting, Bron, France.ORCID http://orcid.org/0000-0001-6045-2103
Elise GeorgesNetris Pharma, Lyon, France.
Jean-Yves ScoazecFaculté de Médecine, Université Paris Saclay, Paris, France.ORCID http://orcid.org/0000-0003-1604-6823
Jerome CrosDepartment of Pathology-INSERM UMR1149, Hôpital Beaujon AP-HP, Université Paris Cité, Paris, France.ORCID http://orcid.org/0000-0002-4935-3865
Sébastien HazardNetris Pharma, Lyon, France.ORCID http://orcid.org/0000-0001-5740-1188
Benjamin DucarougeNetris Pharma, Lyon, France.ORCID http://orcid.org/0000-0002-6701-0508
Thomas DecaensUniv. Grenoble Alpes, Hepato-Gastroenterology and Digestive Oncology, CHU Grenoble Alpes, Grenoble, France.
Agnès BernetUniversité Lyon 1, Centre Léon Bérard, INSERM U1052-CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon (CRCL), Apoptosis, Cancer and Development Laboratory, Equipe Labellisée 'La Ligue', LabEx DEVweCAN, Institut PLAsCAN, Lyon, France.ORCID http://orcid.org/0000-0002-8260-9711
Patrick MehlenUniversité Lyon 1, Centre Léon Bérard, INSERM U1052-CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon (CRCL), Apoptosis, Cancer and Development Laboratory, Equipe Labellisée 'La Ligue', LabEx DEVweCAN, Institut PLAsCAN, Lyon, France. patrick.mehlen@lyon.unicancer.fr.ORCID http://orcid.org/0000-0003-1743-5417
Funding
No grant is acknowledged in the PubMed record.
Abstract
Netrin1, a developmental cue, is a master regulator of tumour epithelial-to-mesenchymal transition (EMT)
Indexed as
Antineoplastic Combined Chemotherapy ProtocolsDrug Resistance, NeoplasmNetrin-1Pancreatic NeoplasmsAgedEpithelial-Mesenchymal TransitionFemaleHumansIrinotecanLeucovorinMaleMembrane ProteinsMiddle AgedProgression-Free SurvivalIrinotecanLeucovorinMembrane ProteinsneogeninNetrin-1NTN1 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.